Recurrence factors for myelin oligodendrocyte glycoprotein antibody disease in children and the effect of recurrence prevention regimens.
- Author:
Sa-Ying ZHU
1
;
Jing PENG
1
;
Lei-Lei MAO
1
;
Xiao-Lu DENG
1
;
Ci-Liu ZHANG
1
;
Li-Fen YANG
1
;
Fei YIN
1
;
Fang HE
1
Author Information
1. Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410007, China.
- Publication Type:Journal Article
- MeSH:
Autoantibodies;
Child;
Humans;
Myelin-Oligodendrocyte Glycoprotein;
Optic Neuritis;
Recurrence;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(7):724-729
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical features and recurrence factors of myelin oligodendrocyte glycoprotein (MOG) antibody disease in children and the effect of recurrence prevention regimens.
METHODS:A retrospective analysis was performed on the medical data of 41 children with MOG antibody disease who were hospitalized in the Department of Pediatric Neurology, Xiangya Hospital of Central South University, from December 2014 to September 2020. According to the presence or absence of recurrence, they were divided into a monophasic course group (
RESULTS:For these 41 children, acute disseminated encephalomyelitis was the most common initial manifestation and was observed in 23 children (56%). Of the 41 children, 22 (54%) experienced recurrence, with 57 recurrence events in total, among which optic neuritis was the most common event (17/57, 30%). The proportion of children in the recurrence group who were treated with corticosteroids for less than 3 months in the acute phase was higher than that in the monophasic course group (64%
CONCLUSIONS:More than half of the children with MOG antibody disease may experience recurrence. Most children with recurrence are treated with corticosteroids for less than 3 months in the acute phase. Rituximab and azathioprine may reduce the risk of recurrence.
